Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the clearance of an ...
These newer agents appear to be effective in the treatment of bipolar disorder, especially for those patients with rapid cycling, dysphoric or mixed mania, or neurologic abnormalities.